Cellular Biomedicine Group, Inc.
CBMG
CBMG was delisted on the 19th of February, 2021.
40 hedge funds and large institutions have $59.4M invested in Cellular Biomedicine Group, Inc. in 2019 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 13 increasing their positions, 9 reducing their positions, and 3 closing their positions.
167% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 3
103% more capital invested
Capital invested by funds: $29.3M → $59.4M (+$30.1M)
44% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 9
14% more funds holding
Funds holding: 35 → 40 (+5)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $5K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
+$11.9M |
| 2 |
NAMA
Nikko Asset Management Americas
New York
|
+$7.05M |
| 3 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$6.95M |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$5.19M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
+$908K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$305K |
| 2 |
BlackRock
New York
|
-$215K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$142K |
| 4 |
MIM
MetLife Investment Management
Whippany,
New Jersey
|
-$110K |
| 5 |
MLICM
Metropolitan Life Insurance Company (MetLife)
New York
|
-$80.8K |
CBMG Hedge Fund Activity: Q1 2019 in Review
40 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Cellular Biomedicine Group, Inc. (CBMG) for Q1 2019, worth a combined $59.4M — up 103% from $29.3M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new CBMG positions and 3 closed out — a net gain of 5 holders — while 13 added to existing stakes and 9 trimmed.
The largest buyer was Platinum Investment Management, opening a new position worth an estimated $11.9M. The largest seller was Morgan Stanley, cutting an estimated $305K.
- 40 institutional investors held Cellular Biomedicine Group, Inc. (CBMG) as of Q1 2019, up from 35 in Q4 2018.
- Funds reported $59.4M of Cellular Biomedicine Group, Inc. stock for Q1 2019, up 103% quarter-over-quarter.
- 8 funds opened new Cellular Biomedicine Group, Inc. positions in Q1 2019 and 3 closed out, a net change of +5 holders.
- The largest Cellular Biomedicine Group, Inc. buyer in Q1 2019 was Platinum Investment Management, an estimated $11.9M added.
- The largest Cellular Biomedicine Group, Inc. seller in Q1 2019 was Morgan Stanley, an estimated $305K sold.
Based on aggregated 13F filings for Q1 2019.